RTTNews | Aug 2, 2021 09:53AM EDT

09:52 Monday, August 2, 2021 (RTTNews.com) - Shares of TG Therapeutics Inc. (TGTX) are losing nearly 12% on Monday morning after the company's second-quarter results missed Wall Street estimates.

TGTX is currently trading at $30.99, down $4.00 or 11.44%, on the Nasdaq. The stock has traded between $17.67 and $56.74 in the 52 week period. TG Therapeutics shares have gained nearly 80% in that period.

Net loss was $78.5 million or $0.59 per share for the second quarter, compared to $52.9 million or $0.47 per share last year. Excluding one-time items, the loss was about $62.2 million, wider than last year's $45.5 million. Analysts polled by Thomson Reuters expected a loss of $0.50 per share.

Product revenues were about $1.5 million, compared to $38 thousand last year. Net product revenues represent U.S. sales from sole commercial product, UKONIQ, which received accelerated approval from the FDA on February 5, 2021. Analysts expected revenues of $3.49 million for the quarter.

Read the original article on RTTNews ( https://www.rttnews.com/3214731/tg-therapeutics-down-12-on-quarterly-results.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved